Oncor, The Johns Hopkins University deal

Oncor licensed a patent from the university for genetic diagnosis of prostate cancer. The company said the technology demonstrated that loss of expression of the glutathione-S-transferase gene (GSTP1) predicts development of prostate cancer.

GSTP1 expression is hampered by aberrant methylation of its promoter region. According to ONC, studies at Johns Hopkins show that most prostate tumors had aberrant methylation, whereas normal prostate tissue and benign prostatic hyperplasia tissue from the same individuals showed no GSTP1 methylation changes. ...